Hepatitis B Therapy Pipeline: How Far Are We From Cure- Peter Revill, PhD

APACC 2019

Chemistry from the Microbiome and its role in health and disease- Robert Quinn, PhD

International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2018

Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry

European Meeting on HIV & Hepatitis 2020

Implementing an optimal Advanced HIV Disease (AHD) package of care: Lessons learnt from national service delivery planning in Malawi

INTEREST 2020

Efficacy, Safety and Tolerability of Guideline-Recommended ARVs from Pediatric Clinical Trials: A Systematic Review

International Workshop on HIV Pediatrics 2021

Antiviral therapy of HBV/HCV in China from clinical perspective - Jidong Jia, MD, PhD

Asian Conference on Hepatitis and AIDS (ACHA) 2014

Durable Efficacy of Dolutegravir (Dtg) Plus Lamivudine (3tc) In Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 3-Year Results From the Gemini Studies in Participants From Asian Centers

APACC 2021

Incidence of HIV Infections Among Children Aged Less Than 2 Years Born From HIV Infected Mothers Attending KCMC Hospital in Moshi Tanzania From January 2014 to December 2015.

INTEREST 2020

Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the Gemini Studies in Participants From Asian Centres

APACC 2020

Welcome Message from David Burger | 26th Antiviral PK 2025

26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025